ReviewWorld journal of transplantation2020

Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?

Federico Piñero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.